RMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-21), ResMed's current share price is $217.48. ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $22.84. ResMed's Cyclically Adjusted PS Ratio for today is 9.52.
The historical rank and industry rank for ResMed's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, ResMed's highest Cyclically Adjusted PS Ratio was 18.37. The lowest was 6.12. And the median was 8.65.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
ResMed's adjusted revenue per share data for the three months ended in Mar. 2024 was $8.118. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $22.84 for the trailing ten years ended in Mar. 2024.
The historical data trend for ResMed's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 10.73 | 10.40 | 6.84 | 7.82 | 8.67 |
For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where ResMed's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
ResMed's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 217.48 | / | 22.84 | |
= | 9.52 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, ResMed's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 8.118 | / | 131.7762 | * | 131.7762 | |
= | 8.118 |
Current CPI (Mar. 2024) = 131.7762.
ResMed Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 2.900 | 100.560 | 3.800 |
201409 | 2.666 | 100.428 | 3.498 |
201412 | 2.974 | 99.070 | 3.956 |
201503 | 2.958 | 99.621 | 3.913 |
201506 | 3.170 | 100.684 | 4.149 |
201509 | 2.893 | 100.392 | 3.797 |
201512 | 3.214 | 99.792 | 4.244 |
201603 | 3.214 | 100.470 | 4.215 |
201606 | 3.661 | 101.688 | 4.744 |
201609 | 3.276 | 101.861 | 4.238 |
201612 | 3.733 | 101.863 | 4.829 |
201703 | 3.603 | 102.862 | 4.616 |
201706 | 3.900 | 103.349 | 4.973 |
201709 | 3.650 | 104.136 | 4.619 |
201712 | 4.180 | 104.011 | 5.296 |
201803 | 4.109 | 105.290 | 5.143 |
201806 | 4.323 | 106.317 | 5.358 |
201809 | 4.084 | 106.507 | 5.053 |
201812 | 4.511 | 105.998 | 5.608 |
201903 | 4.588 | 107.251 | 5.637 |
201906 | 4.865 | 108.070 | 5.932 |
201909 | 4.694 | 108.329 | 5.710 |
201912 | 5.057 | 108.420 | 6.146 |
202003 | 5.282 | 108.902 | 6.391 |
202006 | 5.271 | 108.767 | 6.386 |
202009 | 5.147 | 109.815 | 6.176 |
202012 | 5.464 | 109.897 | 6.552 |
202103 | 5.283 | 111.754 | 6.229 |
202106 | 5.975 | 114.631 | 6.869 |
202109 | 6.156 | 115.734 | 7.009 |
202112 | 6.086 | 117.630 | 6.818 |
202203 | 5.882 | 121.301 | 6.390 |
202206 | 6.220 | 125.017 | 6.556 |
202209 | 6.459 | 125.227 | 6.797 |
202212 | 7.013 | 125.222 | 7.380 |
202303 | 7.578 | 127.348 | 7.842 |
202306 | 7.601 | 128.729 | 7.781 |
202309 | 7.474 | 129.860 | 7.584 |
202312 | 7.881 | 129.419 | 8.025 |
202403 | 8.118 | 131.776 | 8.118 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of ResMed's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Brett Sandercock | officer: Chief Financial Officer | 17 GUINEVIERE COURT, CASTLE HILL, NEW SOUTH WALES C3 2154 |
Michael J. Farrell | officer: Chief Executive Officer | C/O REMED INC, 9001 SPECTRUM CTR. BLVD., SAN DIEGO, CA 92123 |
Michael J Rider | officer: Global General Counsel | 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123 |
Robert Andrew Douglas | officer: President and COO | 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106 |
Kaushik Ghoshal | officer: President, SaaS Business | 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123 |
David Pendarvis | officer: Chief Administration Officer | REDMED INC, 14040 DANLELSON ST, POWAY CA 92064 |
Karen Drexler | director | C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Justin Leong | officer: President, Asia and LATAM | C/O RESMED INC, 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123 |
Desney Tan | director | 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123 |
John Hernandez | director | 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123 |
Lucile Blaise | officer: President, Sleep & RC Business | RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123 |
Peter C Farrell | director | RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857 |
James Hollingshead | officer: President, Sleep Business | C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123 |
Carol Burt | director | C/O WELLCARE HEALTH PLANS, INC., 8725 HENDERSON ROAD, TAMPA FL 33634 |
Resmed Inc | director | 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123 |
From GuruFocus
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024